Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing

被引:1
|
作者
Salama, Engie [1 ]
Lam, Stepfanie [1 ]
Gonsalves, Wilson, I [2 ]
Tzachanis, Dimitrios [3 ]
Momper, Jeremiah D. [1 ]
Saunders, Ila M. [1 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0657, La Jolla, CA 92093 USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Univ Calif San Diego Hlth, Moores Canc Ctr, La Jolla, CA USA
关键词
multiple myeloma; pharmacokinetics; lenalidomide; renal impairment; CREATININE CLEARANCE; PHARMACOKINETICS; RECOMMENDATIONS;
D O I
10.1177/10600280221087218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Lenalidomide is an immunomodulatory drug used to treat multiple myeloma that requires renal dosing adjustment based on Cockcroft-Gault (CG). Various equations to estimate kidney function exist and pose a potential issue with lenalidomide dosing. Objective The objective of this analysis was to evaluate the impact of estimating kidney function in newly diagnosed multiple myeloma patients with CG, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and their potential impact on lenalidomide dosing. Methods Data from 1121 multiple myeloma patients at the time of diagnosis acquired from the Mayo Clinic were used to calculate creatinine clearance (CrCl) using Cockcroft-Gault with actual body weight (CG(ABW)), ideal body weight (CG(IBW)), or adjusted body weight (CG(AdjBW)); MDRD; and CKD-EPI for each subject. Discordances in dosing were then analyzed, and lenalidomide exposure was calculated for each subject to assess impact on pharmacokinetics of lenalidomide for patients who received discordant doses. Results Overall, approximately 16% of patients received a discordant dose when using MDRD or CKD-EPI instead of CG(ABW). The most common dose discordance was the decrease of a full dose of lenalidomide 25 mg when using CG(ABW) down to 10 mg and when using MDRD or CKD-EPI with 53.8% to 55.6% of all discordances in this category. When assessing different body weights, the most common discordance was a decrease from 25 to 10 mg when using CG(IBW) instead of CG(ABW); the same trend was observed when using CG(AdjBW) instead as well. Patients were also at risk of over- or underexposure based on area under the concentration versus time curve (AUC) for discordant dosing. Conclusion and Relevance A significant proportion of patients are at risk of under- or overdose of lenalidomide if CKD-EPI or MDRD are used instead of CG(ABW). Physicians should use CG(ABW) when estimating renal function to dose lenalidomide.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
  • [31] Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Hultcrantz, Malin
    Hassoun, Hani
    Korde, Neha
    MacLachlan, Kylee
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn Rose
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather J.
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Pianko, Matthew J.
    Burge, Miranda
    Barnett, Kelly
    Salcedo, Meghan
    Caple, Julia
    Tran, Linh
    Blaslov, Jenna
    Shekarkhand, Tala
    Hamid, Selena
    Nemirovsky, David
    Derkach, Andriy
    Arisa, Oluwatobi
    Peer, Cody J.
    Figg, William D.
    Usmani, Saad Z.
    Landgren, Ola
    Lesokhin, Alexander M.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [32] High Implementation Adherence to Lenalidomide in Patients with Multiple Myeloma
    Leader, Avi
    Magen, Hila
    Amitai, Irina
    Pironet, Antoine
    Tousset, Eric
    Rozental, Alon
    De Geest, Sabina
    Vaxman, Iuliana
    Raanani, Pia
    Nagler, Arnon
    BLOOD, 2022, 140 : 8068 - 8069
  • [33] Effectiveness of Lenalidomide in Patients with Relapsed or Progressive Multiple Myeloma
    Amor, A. A.
    Casanova, M.
    Fuertes, M.
    Guzman, J. L.
    Bueno, B. A.
    Giraldo, P.
    Canovas, A.
    Ibanez, A.
    Castillo, I.
    Blanes, M.
    Rios, E.
    Rodriguez, J. N.
    Palomera, L.
    Hernandez, M. T.
    Oriol, A.
    Sancho, E.
    Menchaca, C.
    Vercher, J.
    Gonzalez, A. P.
    Arilia, M. J.
    Ramirez, G.
    Perez, R.
    Asensio, A.
    de la Serna, J.
    Osorio, S.
    Aguilar, C.
    Anso, V.
    Calvo, J. M.
    Lopez, L.
    Lopez, A.
    Olalla, J. I.
    Hernandez, J. M.
    Petit, J.
    Rios, P.
    Villalon, L.
    Garcia, I.
    Garcia, A.
    Larregla, S.
    Garcia-Escribano, F. L.
    Lahuerta, J. J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S17 - S18
  • [34] Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
    Sanchez, Larysa
    Moshier, Erin
    Coltoff, Alexander
    Mustafa, Ali
    Pan, Darren
    Cho, Hearn Jay
    Jagannath, Sundar
    Madduri, Deepu
    Parekh, Samir
    Richard, Shambavi
    Richter, Joshua
    Chari, Ajai
    BLOOD, 2019, 134
  • [35] Repeated Lenalidomide Treatment in Patients With Relapsed Multiple Myeloma
    Stork, Martin
    Pour, Ludek
    Adam, Zdenek
    Krejci, Marta
    Sandecka, Viera
    Vaculova, Jitka
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E56 - E57
  • [36] Lenalidomide in relapsed patients with Multiple Myeloma - Focus on Polyneuropathy
    Goldschmidt, H.
    Heiss, C.
    Klein, U.
    Egerer, G.
    Raab, M. -S.
    Hillengass, J.
    Neben, K.
    ONKOLOGIE, 2011, 34 : 158 - 158
  • [37] LENALIDOMIDE AS CONSOLIDATION/MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS
    Gagliardi, A.
    Della Cioppa, P.
    Lucania, A.
    Villa, M. R.
    Esposito, M.
    Improta, S.
    Izzo, G. Nitrato
    Mastrullo, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 593 - 593
  • [38] Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma
    Lum, Erik L.
    Huang, Edmund
    Bunnapradist, Suphamai
    Thu Pham
    Danovitch, Gabriel
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 69 (05) : 701 - 704
  • [39] Estimation of kidney function for medication dosing in adult patients with chronic kidney disease: a practice update
    Mirkov, Sanja
    Scuderi, Carla
    Lloyd, Jess
    Coutsouvelis, John
    O'Connor, Shaun
    Potts, Simon
    Newman, Suzanne
    Roberts, Jason
    JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2024, 54 (01) : 94 - 106
  • [40] Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd - R) In High Risk Smoldering Multiple Myeloma Patients
    Landgren, Ola
    Mailankody, Sham
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Zingone, Adriana
    Costello, Rene
    Burton, Debra
    Zhang, Yong
    Wu, Peter
    Carter, George
    Mulquin, Marcia
    Zuchlinski, Diamond
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Lindenberg, Liza
    Kurdziel, Karen
    Choyke, Peter
    Steinberg, Seth M.
    Roschewski, Mark
    Korde, Neha
    BLOOD, 2013, 122 (21)